secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nutex Health Inc. (NUTX)
CIK:        0001479681
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001479681-25-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutex Health reports FY 2024 net income of $52.2M vs loss of $45.8M in 2023; revenue up 93.8% to $479.9M
--------------------------------------------------------------------------------

- FY 2024 total revenue $479.9M (+93.8% YoY); net income $52.2M vs net loss $45.8M in 2023.
- Diluted EPS $9.71 vs $(10.39); Adjusted EBITDA $123.7M up 1,045% from $10.8M.
- Arbitration process added $169.7M more revenue in 2024 than 2023; drove 73.1% of revenue growth.
- Q4 2024 revenue $257.6M (+270% YoY); operating income $114.2M vs operating loss $26.1M.
- Cash from ops $23.2M; total assets $655.3M; long-term debt $22.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479681/000147968125000008/0001479681-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479681/000147968125000008/nutx-20250331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001479681-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer